Omidenepag: A New Category of Topical Glaucoma Therapy

Drs. Amanda Bicket and Lori Provencher join Dr. Andrew Pouw to discuss omidenepag isopropyl (Omlonti), the recently FDA-approved eye drop for treating elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

CME Information

Release: December 29, 2022; expires December 29, 2025

Disclosures: 
Planner/Faculty: Dr. Pouwreports no relevant financial disclosures.
Faculty: Drs. Bicket and Provencher report no relevant financial disclosures.
Review Panel: Dr. Mazeyar Saboori receives consulting and lecture fees from Aerie Pharmaceuticals. The following reviewers report no financial disclosures: Jeffrey D. Henderer, MD; Danah Albreiki, MBBS; Ashiyani Nariani, MD, MPH; Annie Moreau, MD; and Allison Umfress, MD.

Learning Objective: Upon completion of this episode, the listener should be able to describe the mechanism of action of omidenepag isopropyl and its use and potential complications in patients with primary open-angle glaucoma.

Audience: This activity is intended for comprehensive ophthalmologists.

Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.